tetano
Editor, Senior Moderator
Int J Prison Health (2024)
. 2024 Sep 17;ahead-of-print(ahead-of-print).
doi: 10.1108/IJOPH-01-2024-0005. Prevalence of COVID-19 in prison population: a meta-analysis of 35 studies
SeyedAhmad SeyedAlinaghi[SUP] 1 [/SUP], Soudabeh Yarmohammadi[SUP] 2 [/SUP], Farid Farahani Rad[SUP] 3 [/SUP], Muhammad Ali Rasheed[SUP] 3 [/SUP], Mohammad Javaherian[SUP] 3 [/SUP], Amir Masoud Afsahi[SUP] 4 [/SUP], Haleh Siami[SUP] 5 [/SUP], AmirBehzad Bagheri[SUP] 6 [/SUP], Ali Zand[SUP] 3 [/SUP], Omid Dadras[SUP] 1 [/SUP], Esmaeil Mehraeen[SUP] 7 [/SUP]
Affiliations
Purpose: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Considering the restricted and enclosed nature of prisons and closed environments and the prolonged and close contact between individuals, COVID-19 is more likely to have a higher incidence in these settings. This study aims to assess the prevalence of COVID-19 among prisoners.
Design/methodology/approach: Papers published in English from 2019 to July 7, 2023, were identified using relevant keywords such as prevalence, COVID-19 and prisoner in the following databases: PubMed/MEDLINE, Scopus and Google Scholar. For the meta-analysis of the prevalence, Cochrane's Q statistics were calculated. A random effect model was used due to the heterogeneity in COVID-19 prevalence across included studies in the meta-analysis. All analyses were performed in STATA-13.
Findings: The pooled data presented a COVID-19 prevalence of 20% [95%CI: 0.13, 0.26] and 24% [95%CI: 0.07, 0.41], respectively, in studies that used PCR and antibody tests. Furthermore, two study designs, cross-sectional and cohort, were used. The results of the meta-analysis showed studies with cross-sectional and cohort designs reported 20% [95%CI: 0.11, 0.29] and 25% [95%CI: 0.13, 0.38], respectively.
Originality/value: Through more meticulous planning, it is feasible to reduce the number of individuals in prison cells, thereby preventing the further spread of COVID-19.
Keywords: COVID-19; Prevalence; Prisoners; SARS-CoV-2.
. 2024 Sep 17;ahead-of-print(ahead-of-print).
doi: 10.1108/IJOPH-01-2024-0005. Prevalence of COVID-19 in prison population: a meta-analysis of 35 studies
SeyedAhmad SeyedAlinaghi[SUP] 1 [/SUP], Soudabeh Yarmohammadi[SUP] 2 [/SUP], Farid Farahani Rad[SUP] 3 [/SUP], Muhammad Ali Rasheed[SUP] 3 [/SUP], Mohammad Javaherian[SUP] 3 [/SUP], Amir Masoud Afsahi[SUP] 4 [/SUP], Haleh Siami[SUP] 5 [/SUP], AmirBehzad Bagheri[SUP] 6 [/SUP], Ali Zand[SUP] 3 [/SUP], Omid Dadras[SUP] 1 [/SUP], Esmaeil Mehraeen[SUP] 7 [/SUP]
Affiliations
- PMID: 39267228
- DOI: 10.1108/IJOPH-01-2024-0005
Purpose: COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Considering the restricted and enclosed nature of prisons and closed environments and the prolonged and close contact between individuals, COVID-19 is more likely to have a higher incidence in these settings. This study aims to assess the prevalence of COVID-19 among prisoners.
Design/methodology/approach: Papers published in English from 2019 to July 7, 2023, were identified using relevant keywords such as prevalence, COVID-19 and prisoner in the following databases: PubMed/MEDLINE, Scopus and Google Scholar. For the meta-analysis of the prevalence, Cochrane's Q statistics were calculated. A random effect model was used due to the heterogeneity in COVID-19 prevalence across included studies in the meta-analysis. All analyses were performed in STATA-13.
Findings: The pooled data presented a COVID-19 prevalence of 20% [95%CI: 0.13, 0.26] and 24% [95%CI: 0.07, 0.41], respectively, in studies that used PCR and antibody tests. Furthermore, two study designs, cross-sectional and cohort, were used. The results of the meta-analysis showed studies with cross-sectional and cohort designs reported 20% [95%CI: 0.11, 0.29] and 25% [95%CI: 0.13, 0.38], respectively.
Originality/value: Through more meticulous planning, it is feasible to reduce the number of individuals in prison cells, thereby preventing the further spread of COVID-19.
Keywords: COVID-19; Prevalence; Prisoners; SARS-CoV-2.